Загрузка...
Metabolic Targets in Nonalcoholic Fatty Liver Disease
The prevalence and diagnosis of nonalcoholic fatty liver disease (NAFLD) is on the rise worldwide and currently has no FDA-approved pharmacotherapy. The increase in disease burden of NAFLD and a more severe form of this progressive liver disease, nonalcoholic steatohepatitis (NASH), largely mirrors...
Сохранить в:
| Опубликовано в: : | Cell Mol Gastroenterol Hepatol |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elsevier
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6698700/ https://ncbi.nlm.nih.gov/pubmed/31004828 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcmgh.2019.04.007 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|